Relationship between structure and P-glycoprotein inhibitory activity of dimeric peptides related to the Dmt-Tic pharmacophore

被引:3
作者
Ambo, Akihiro [1 ]
Ohkatsu, Hiromichi [1 ]
Minamizawa, Motoko [1 ]
Watanabe, Hideko [1 ]
Sugawara, Shigeki [1 ]
Nitta, Kazuo [1 ]
Tsuda, Yuko [2 ]
Okada, Yoshio [2 ]
Sasaki, Yusuke [1 ]
机构
[1] Tohoku Pharmaceut Univ, Aoba Ku, Sendai, Miyagi 9818558, Japan
[2] Kobe Gakuin Univ, Chuo Ku, Kobe, Hyogo 6508586, Japan
关键词
Dimeric peptide analogs; P-glycoprotein inhibitory activity; Structure-activity relationship; Dmt-Tic pharmacophore; BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE; D-PENICILLAMINE(2,5) ENKEPHALIN; ANALOGS; ANTINOCICEPTION; TRANSPORTER; BINDING; CANCER; POTENT; DRUGS;
D O I
10.1016/j.bmcl.2012.01.107
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To develop novel inhibitors of P-glycoprotein (P-gp), dimeric peptides related to an opioid peptide containing the Dmt-Tic pharmacophore were synthesized and their P-gp inhibitory activities were analyzed. Of the 30 analogs synthesized, N-alpha,N-epsilon-[(CH3)(2)Mle-Tic](2)Lys-NH2 and its D-Lys analog were found to exhibit potent P-gp inhibitory activity, twice that of verapamil, in doxorubicin-resistant K562 cells. Structure-activity studies indicated that the correct hydrophobicity and spacer length between two aromatic rings are important structural elements in this series of analogs for inhibition of P-gp. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2192 / 2194
页数:3
相关论文
共 19 条
[1]   Opioid receptor-like 1 (ORL1) receptor binding and the biological properties of Ac-Arg-Tyr-Tyr-Arg-lie-Arg-NH2 and its analogs [J].
Ambo, A. ;
Kohara, H. ;
Kawano, S. ;
Sasaki, Y. .
JOURNAL OF PEPTIDE SCIENCE, 2007, 13 (10) :672-678
[2]   DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE [J].
BELL, DR ;
GERLACH, JH ;
KARTNER, N ;
BUICK, RN ;
LING, V .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :311-315
[3]   Enhanced antinociception of the model opioid peptide [D-Penicillamine2,5] enkephalin by P-glycoprotein modulation [J].
Chen, CP ;
Pollack, GM .
PHARMACEUTICAL RESEARCH, 1999, 16 (02) :296-301
[4]  
Chen CP, 1998, J PHARMACOL EXP THER, V287, P545
[5]   BLOOD-BRAIN-BARRIER RESTRICTION OF PEPTIDES AND LOW UPTAKE OF ENKEPHALINS [J].
CORNFORD, EM ;
BRAUN, LD ;
CRANE, PD ;
OLDENDORF, WH .
ENDOCRINOLOGY, 1978, 103 (04) :1297-1303
[6]   EXPRESSION OF A MULTIDRUG-RESISTANCE GENE IN HUMAN-TUMORS AND TISSUES [J].
FOJO, AT ;
UEDA, K ;
SLAMON, DJ ;
POPLACK, DG ;
GOTTESMAN, MM ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (01) :265-269
[7]  
GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163
[8]  
HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
[9]   From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance [J].
Litman, T ;
Druley, TE ;
Stein, WD ;
Bates, SE .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (07) :931-959
[10]   Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity [J].
Litman, T ;
Zeuthen, T ;
Skovsgaard, T ;
Stein, WD .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1997, 1361 (02) :159-168